Literature DB >> 17869976

Susceptibility patterns of Candida species recovered from Canadian intensive care units.

Michel Laverdiere1, Annie-Claude Labbé, Christiane Restieri, Coleman Rotstein, Daren Heyland, Sheldon Madger, Thomas Stewart.   

Abstract

OBJECTIVE: The objective of this study was to determine the speciation and susceptibility patterns of Candida species recovered from Canadian intensive care units (ICUs) during a 1-day point-prevalence study on fungal colonization/infection in Canadian ICUs. METHODS AND
SETTING: Blood, urine, respiratory tract, rectal, and wound fungal cultures were performed for 357 patients present at any time during a single-day 24-hour period in 35 Canadian ICUs. Comparative in vitro activities of amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, micafungin, anidulafungin, and aminocandin were determined.
RESULTS: Four hundred fifteen yeasts (409 Candida species and 6 non-Candida yeasts) were recovered. Almost 50% of the patients were found to have positive respiratory tract or rectal cultures. Candida albicans accounted for 72% of the Candida species isolated, followed by Candida glabrata (16%), Candida tropicalis (5%), Candida parapsilosis (3%), Candida krusei (2%), and other Candida species or nonspeciated isolates (2%). Minimum inhibitory concentrations (milligrams per liter) at which 90% of the strains were inhibited were 0.06 for micafungin as well as anidulafungin, 0.12 for voriconazole, 0.25 for itraconazole, posaconazole, as well as aminocandin, 1 for amphotericin B, and 4 for fluconazole. Only 4% of the isolates were resistant to fluconazole and/or itraconazole.
CONCLUSIONS: Candida albicans is the predominant species colonizing Canadian ICU patients. Overall, the triazoles, both older and new compounds, and the echinocandins have excellent in vitro antifungal activities against Candida species recovered from Canadian ICUs patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869976     DOI: 10.1016/j.jcrc.2006.10.038

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  10 in total

1.  The Prospective Antifungal Therapy Alliance(®) registry: A two-centre Canadian experience.

Authors:  Shariq Haider; Coleman Rotstein; David Horn; Michel Laverdiere; Nkechi Azie
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

Review 2.  Emerging drugs and vaccines for candidemia.

Authors:  Brad Moriyama; Lori A Gordon; Matthew McCarthy; Stacey A Henning; Thomas J Walsh; Scott R Penzak
Journal:  Mycoses       Date:  2014-10-08       Impact factor: 4.377

3.  Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.

Authors:  A Sellami; H Sellami; S Néji; F Makni; S Abbes; F Cheikhrouhou; H Chelly; M Bouaziz; B Hammami; M Ben Jemaa; S Khaled; A Ayadi
Journal:  Mycopathologia       Date:  2010-12-19       Impact factor: 2.574

4.  Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Araceli Monzon; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

5.  Candiduria in children and susceptibility patterns of recovered Candida species to antifungal drugs in Ahvaz.

Authors:  Zahra Seifi; Maryam Azish; Zahra Salehi; Ali Zarei Mahmoudabadi; Ahmad Shamsizadeh
Journal:  J Nephropathol       Date:  2013-04-01

Review 6.  Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis.

Authors:  Benoît P Guery; Maiken C Arendrup; Georg Auzinger; Elie Azoulay; Márcio Borges Sá; Elizabeth M Johnson; Eckhard Müller; Christian Putensen; Coleman Rotstein; Gabriele Sganga; Mario Venditti; Rafael Zaragoza Crespo; Bart Jan Kullberg
Journal:  Intensive Care Med       Date:  2008-10-30       Impact factor: 17.440

7.  Invasive Candidiasis in Critically Ill Patients: A Prospective Cohort Study in Two Tertiary Care Centers.

Authors:  Hasan M Al-Dorzi; Hussam Sakkijha; Raymond Khan; Tarek Aldabbagh; Aron Toledo; Pendo Ntinika; Sameera M Al Johani; Yaseen M Arabi
Journal:  J Intensive Care Med       Date:  2018-04-08       Impact factor: 3.510

8.  A seven-year surveillance of Candida bloodstream infection at a university hospital in KSA.

Authors:  Tariq S Al-Musawi; Wala A Alkhalifa; Norah A Alasaker; Jawad U Rahman; Amani M Alnimr
Journal:  J Taibah Univ Med Sci       Date:  2020-12-30

9.  Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards.

Authors:  Sara Mazzanti; Lucia Brescini; Gianluca Morroni; Elena Orsetti; Antonella Pocognoli; Abele Donati; Elisabetta Cerutti; Christopher Munch; Roberto Montalti; Francesco Barchiesi
Journal:  PLoS One       Date:  2021-05-26       Impact factor: 3.240

10.  Species distribution and susceptibility profile of Candida species in a Brazilian public tertiary hospital.

Authors:  Ariane Bruder-Nascimento; Carlos Henrique Camargo; Maria Fátima Sugizaki; Terue Sadatsune; Augusto Cezar Montelli; Alessandro Lia Mondelli; Eduardo Bagagli
Journal:  BMC Res Notes       Date:  2010-01-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.